NCT04633889View on ClinicalTrials.gov

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

August 26, 2024

Study Completion Date

December 14, 2024

Conditions
Acute Kidney Injury
Interventions
DRUG

Deferoxamine

Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours

DRUG

Normal saline

Normal saline (240mL) intravenous infusion over 12 hours

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Brigham and Women's Hospital

OTHER